Cargando…
SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier España, S.L.U.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904140/ https://www.ncbi.nlm.nih.gov/pubmed/35281411 http://dx.doi.org/10.1016/j.vacun.2022.03.001 |
| _version_ | 1784664891451244544 |
|---|---|
| author | Ghazvini, Kiarash Keikha, Masoud |
| author_facet | Ghazvini, Kiarash Keikha, Masoud |
| author_sort | Ghazvini, Kiarash |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8904140 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier España, S.L.U. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89041402022-03-09 SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status Ghazvini, Kiarash Keikha, Masoud Vacunas Letter to the Editor Elsevier España, S.L.U. 2022-05 2022-03-09 /pmc/articles/PMC8904140/ /pubmed/35281411 http://dx.doi.org/10.1016/j.vacun.2022.03.001 Text en © 2022 Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Ghazvini, Kiarash Keikha, Masoud SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status |
| title | SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status |
| title_full | SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status |
| title_fullStr | SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status |
| title_full_unstemmed | SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status |
| title_short | SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status |
| title_sort | sars cov2 mrna vaccines: prolonged dosing intervals and anti-sars-cov-2 immunity status |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904140/ https://www.ncbi.nlm.nih.gov/pubmed/35281411 http://dx.doi.org/10.1016/j.vacun.2022.03.001 |
| work_keys_str_mv | AT ghazvinikiarash sarscov2mrnavaccinesprolongeddosingintervalsandantisarscov2immunitystatus AT keikhamasoud sarscov2mrnavaccinesprolongeddosingintervalsandantisarscov2immunitystatus |